In the meta-analysis of 3 studies 20,28,32 which compared a GLP-1-based therapy against a comparator, GLP-1-based therapies were found to increase % FMD non-significantly (mean difference [95% CI] in the changes from baseline: 1.65 [0.89, 4.18] %
A 2015 review in the Journal of Clinical Endocrinology confirming that GHRH analogs combined with ghrelin-pathway agonists produce a synergistic GH secretory response that exceeds additive effects when either compound is used alone provides the mechanistic basis for why combination therapy is the standard in supervised clinical settings
How PlexusDx Supports a More Personalized Approach PlexusDx's Precision Peptide Genetic Test reveals genetic predispositions in GIPR, FTO, and MC4R pathways that may help provide context for your individual GLP-1 response and weight-stability risk
A consultation allows your provider to review your medical history, current medications, weight history, prior attempts, lifestyle patterns, and goals before making recommendations
Clinical presentation of type 2 diabetes